{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-119408","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.590117+00:00","generated_at":"2026-05-21T09:18:12.343850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025","bullets":["Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.","Cash and equivalents $101.0M as of March 31, 2025, expected to fund operations into Q4 2026.","R&D expenses $6.0M (up from $2.0M YoY) driven by TH103 Phase 1 trial initiation.","Phase 1 trial of TH103 for nAMD actively enrolling; initial clinical data expected Q4 2025.","Completed merger with AlloVir in March 2025; appointed Leone Patterson to Board and Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-119408","json":"https://secwatch.observer/filing/0001193125-25-119408.json","markdown":"https://secwatch.observer/filing/0001193125-25-119408.md","text":"https://secwatch.observer/filing/0001193125-25-119408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/0001193125-25-119408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:18:12.343850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}